1802 related articles for article (PubMed ID: 33710753)
1. Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.
Biever P; Staudacher DL; Sommer MJ; Triebel H; Neukamm MA; Bode C; Supady A; Lother A
Pharmacol Res Perspect; 2021 Apr; 9(2):e00743. PubMed ID: 33710753
[TBL] [Abstract][Full Text] [Related]
2. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.
Alvarez JC; Moine P; Etting I; Annane D; Larabi IA
Clin Chem Lab Med; 2020 Aug; 58(9):1461-1468. PubMed ID: 32573468
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
Habler K; Brügel M; Teupser D; Liebchen U; Scharf C; Schönermarck U; Vogeser M; Paal M
J Pharm Biomed Anal; 2021 Mar; 196():113935. PubMed ID: 33548872
[TBL] [Abstract][Full Text] [Related]
4. Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies.
Xiao D; John Ling KH; Tarnowski T; Humeniuk R; German P; Mathias A; Chu J; Chen YS; van Ingen E
Anal Biochem; 2021 Mar; 617():114118. PubMed ID: 33508271
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.
Avataneo V; de Nicolò A; Cusato J; Antonucci M; Manca A; Palermiti A; Waitt C; Walimbwa S; Lamorde M; di Perri G; D'Avolio A
J Antimicrob Chemother; 2020 Jul; 75(7):1772-1777. PubMed ID: 32361744
[TBL] [Abstract][Full Text] [Related]
6. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb S; Reeves AA
J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
[TBL] [Abstract][Full Text] [Related]
7. A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum.
Reckers A; Wu AHB; Ong CM; Gandhi M; Metcalfe J; Gerona R
J Antimicrob Chemother; 2021 Jun; 76(7):1865-1873. PubMed ID: 33864090
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
[TBL] [Abstract][Full Text] [Related]
9. Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
Tempestilli M; Ascoli Bartoli T; Benvenuto D; Stazi GV; Marchioni L; Nicastri E; Agrati C
J Antimicrob Chemother; 2022 Sep; 77(10):2683-2687. PubMed ID: 35848782
[TBL] [Abstract][Full Text] [Related]
10. Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat.
Du P; Wang G; Yang S; Li P; Liu L
Anal Bioanal Chem; 2021 Sep; 413(23):5811-5820. PubMed ID: 34302183
[TBL] [Abstract][Full Text] [Related]
11. Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.
Sato T; Maekawa M; Mano N; Abe T; Yamaguchi H
J Pharm Pharm Sci; 2021; 24():227-236. PubMed ID: 34048668
[TBL] [Abstract][Full Text] [Related]
12. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Sun D
AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
[TBL] [Abstract][Full Text] [Related]
13. Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats.
Yang L; Lin IH; Lin LC; Dalley JW; Tsai TH
EBioMedicine; 2022 Jul; 81():104095. PubMed ID: 35671622
[TBL] [Abstract][Full Text] [Related]
14. Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.
Yan VC; Muller FL
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988821
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
Sörgel F; Malin JJ; Hagmann H; Kinzig M; Bilal M; Eichenauer DA; Scherf-Clavel O; Simonis A; El Tabei L; Fuhr U; Rybniker J
J Antimicrob Chemother; 2021 Feb; 76(3):825-827. PubMed ID: 33251541
[No Abstract] [Full Text] [Related]
16. Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction.
Sukeishi A; Itohara K; Yonezawa A; Sato Y; Matsumura K; Katada Y; Nakagawa T; Hamada S; Tanabe N; Imoto E; Kai S; Hirai T; Yanagita M; Ohtsuru S; Terada T; Ito I
CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):94-103. PubMed ID: 34793625
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: Hyperinflammatory Syndrome and Hemoadsorption with CytoSorb.
Masmouei B; Harorani M; Bazrafshan MR; Karimi Z
Blood Purif; 2021; 50(6):976-978. PubMed ID: 33326959
[No Abstract] [Full Text] [Related]
18. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
Leegwater E; Moes DJAR; Bosma LBE; Ottens TH; van der Meer IM; van Nieuwkoop C; Wilms EB
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0025422. PubMed ID: 35647646
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability study following a single dose intravenous and buccal administration of remdesivir in rabbits.
Szente L; Renkecz T; Sirok D; Stáhl J; Hirka G; Puskás I; Sohajda T; Fenyvesi É
Int J Pharm; 2022 May; 620():121739. PubMed ID: 35421532
[TBL] [Abstract][Full Text] [Related]
20. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia.
Corcione S; De Nicolò A; Montrucchio G; Scabini S; Avataneo V; Bonetto C; Mornese Pinna S; Cusato J; Canta F; Urbino R; Di Perri G; Brazzi L; De Rosa FG; D'Avolio A
Br J Clin Pharmacol; 2021 Dec; 87(12):4861-4867. PubMed ID: 33990984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
